

Fabienne Thomas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2340077/publications.pdf>

Version: 2024-02-01

60
papers

1,600
citations

279487

23
h-index

315357

38
g-index

71
all docs

71
docs citations

71
times ranked

2275
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. <i>Neuro-Oncology</i> , 2011, 13, 109-118. | 0.6 | 137 |
| 2 | <i>UGT1A1</i> genotype and irinotecan therapy: general review and implementation in routine practice. <i>Fundamental and Clinical Pharmacology</i> , 2015, 29, 219-237. | 1.0 | 91 |
| 3 | In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 57, 709-718. | 1.1 | 86 |
| 4 | Dendrogenin A drives LXR to trigger lethal autophagy in cancers. <i>Nature Communications</i> , 2017, 8, 1903. | 5.8 | 84 |
| 5 | New advances in DPYD genotype and risk of severe toxicity under capecitabine. <i>PLoS ONE</i> , 2017, 12, e0175998. | 1.1 | 82 |
| 6 | Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma. <i>European Journal of Cancer</i> , 2009, 45, 2316-2323. | 1.3 | 76 |
| 7 | Pharmacokinetics of Oxaliplatin During Open Versus Laparoscopically Assisted Heated Intraoperative Intraperitoneal Chemotherapy (HIPEC): An Experimental Study. <i>Annals of Surgical Oncology</i> , 2008, 15, 339-344. | 0.7 | 73 |
| 8 | Pilot Study of Neoadjuvant Treatment with Erlotinib in Nonmetastatic Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2007, 13, 7086-7092. | 3.2 | 68 |
| 9 | Thymidylate Synthase Genotype-Directed Neoadjuvant Chemoradiation for Patients With Rectal Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 875-883. | 0.8 | 58 |
| 10 | Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer. <i>British Journal of Cancer</i> , 2011, 105, 1654-1662. | 2.9 | 49 |
| 11 | Increased Tissue Diffusion of Oxaliplatin During Laparoscopically Assisted Versus Open Heated Intraoperative Intraperitoneal Chemotherapy (HIPEC). <i>Annals of Surgical Oncology</i> , 2008, 15, 3623-3624. | 0.7 | 40 |
| 12 | Cystatin C as a New Covariate to Predict Renal Elimination of Drugs. <i>Clinical Pharmacokinetics</i> , 2005, 44, 1305-1316. | 1.6 | 39 |
| 13 | Pharmacogenetics-based personalized therapy: Levels of evidence and recommendations from the French Network of Pharmacogenetics (RNPGe). <i>Therapie</i> , 2017, 72, 185-192. | 0.6 | 38 |
| 14 | Population Analysis of Erlotinib in Adults and Children Reveals Pharmacokinetic Characteristics as the Main Factor Explaining Tolerance Particularities in Children. <i>Clinical Cancer Research</i> , 2011, 17, 4862-4871. | 3.2 | 35 |
| 15 | Genotyping of a family with a novel deleterious <i>DPYD</i> mutation supports the pretherapeutic screening of DPD deficiency with dihyouracil/uracil ratio. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 99, 235-242. | 2.3 | 33 |
| 16 | Serum Cystatin C is a Better Marker of Topotecan Clearance than Serum Creatinine. <i>Clinical Cancer Research</i> , 2005, 11, 3038-3044. | 3.2 | 31 |
| 17 | Pharmacogenomics: The Influence of Genomic Variation on Drug Response. <i>Current Topics in Medicinal Chemistry</i> , 2004, 4, 1397-1407. | 1.0 | 31 |
| 18 | Inhibition of OCT2, MATE1 and MATE2-K as a possible mechanism of drug interaction between pazopanib and cisplatin. <i>Pharmacological Research</i> , 2016, 110, 89-95. | 3.1 | 29 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Pharmacogenetics of anti-cancer drugs: State of the art and implementation—Recommendations of the French National Network of Pharmacogenetics. <i>Therapie</i> , 2017, 72, 205-215. | 0.6 | 28 |
| 20 | Preclinical and Clinical Evidence that Deoxy-2-[18F]fluoro-D-glucose Positron Emission Tomography with Computed Tomography Is a Reliable Tool for the Detection of Early Molecular Responses to Erlotinib in Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 4434-4445. | 3.2 | 27 |
| 21 | Genetic diversity of HCV genotype 2 strains in South Western France. <i>Journal of Medical Virology</i> , 2007, 79, 26-34. | 2.5 | 24 |
| 22 | Contribution of the MDRD Equation and of Cystatin C for Renal Function Estimates in Cancer Patients. <i>Medical Oncology</i> , 2006, 23, 63-74. | 1.2 | 23 |
| 23 | Effect of Single Nucleotide Polymorphisms in the Xenobiotic-sensing Receptors NR1I2 and NR1I3 on the Pharmacokinetics and Toxicity of Irinotecan in Colorectal Cancer Patients. <i>Clinical Pharmacokinetics</i> , 2016, 55, 1145-1157. | 1.6 | 22 |
| 24 | Determination of unbound fraction of pazopanib in vitro and in cancer patients reveals albumin as the main binding site. <i>Investigational New Drugs</i> , 2016, 34, 41-48. | 1.2 | 22 |
| 25 | Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1357-1366. | 1.1 | 19 |
| 26 | Factors Affecting Tamoxifen Metabolism in Patients With Breast Cancer: Preliminary Results of the French PHACS Study. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 585-595. | 2.3 | 19 |
| 27 | Model-Based Quantification of Impact of Genetic Polymorphisms and Co-Medications on Pharmacokinetics of Tamoxifen and Six Metabolites in Breast Cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1244-1255. | 2.3 | 19 |
| 28 | Detection of the G>C SNP and rare mutations in the 28-bp repeat of <i>TYMS</i> using gel-based capillary electrophoresis. <i>Pharmacogenomics</i> , 2010, 11, 1751-1756. | 0.6 | 16 |
| 29 | Therapeutic Drug Monitoring of Carboplatin in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors: Pharmacokinetic Results of a Phase II Multicenter Study. <i>Clinical Cancer Research</i> , 2017, 23, 7171-7179. | 3.2 | 15 |
| 30 | Ototoxicity of High-Dose Carboplatin. <i>Journal of Clinical Oncology</i> , 2005, 23, 3649-3650. | 0.8 | 14 |
| 31 | Polymorphisms in <i>SLCO1B3</i> and <i>NR1I2</i> as genetic determinants of hematotoxicity of carboplatin and paclitaxel combination. <i>Pharmacogenomics</i> , 2015, 16, 1439-1450. | 0.6 | 14 |
| 32 | New <i>DPYD</i> variants causing <i>DPD</i> deficiency in patients treated with fluoropyrimidine. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 45-54. | 1.1 | 13 |
| 33 | Population Pharmacokinetics of Ibrutinib and Its Dihydrodiol Metabolite in Patients with Lymphoid Malignancies. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1171-1183. | 1.6 | 13 |
| 34 | Cross-Validation of a Multiplex LC-MS/MS Method for Assaying mAbs Plasma Levels in Patients with Cancer: A GPCO-UNICANCER Study. <i>Pharmaceuticals</i> , 2021, 14, 796. | 1.7 | 13 |
| 35 | Artificial increase of uracilemia during fluoropyrimidine treatment can lead to <i>DPD</i> deficiency misinterpretation. <i>Annals of Oncology</i> , 2021, 32, 810-811. | 0.6 | 10 |
| 36 | Hypoxia Drives Dihydropyrimidine Dehydrogenase Expression in Macrophages and Confers Chemoresistance in Colorectal Cancer. <i>Cancer Research</i> , 2021, 81, 5963-5976. | 0.4 | 10 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Therapeutic drug monitoring and dose adaptation of cisplatin in a newborn with hepatoblastoma: a case report. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 361-365. | 1.1 | 9 |
| 38 | Easy and reliable maximum <i>a posteriori</i> Bayesian estimation of pharmacokinetic parameters with the open-source R package mapbayr. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 1208-1220. | 1.3 | 9 |
| 39 | Irreversible hepatotoxicity after administration of trabectedin to a pleiomorphic sarcoma patient with a rare ABC2 polymorphism: a case report. <i>Pharmacogenomics</i> , 2013, 14, 1389-1396. | 0.6 | 8 |
| 40 | Lethal 5-fluorouracil toxicity in a colorectal patient with severe dihydropyrimidine dehydrogenase (DPD) deficiency. <i>International Journal of Colorectal Disease</i> , 2016, 31, 699-701. | 1.0 | 7 |
| 41 | Phase II trial of TI-CE high dose chemotherapy (HDCT) with drug monitoring for individual carboplatin dosing in patients with relapsed advanced germ cell tumors: A multicentric prospective GETUG trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 401-401. | 0.8 | 6 |
| 42 | Gene expression profiling on pre- and post-erlotinib tumors from patients with head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2013, 35, 809-818. | 0.9 | 5 |
| 43 | Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: The multiparametric approach is not convincing. <i>Seminars in Oncology</i> , 2017, 44, 159-160. | 0.8 | 5 |
| 44 | Limited Sampling Strategy for Determination of Ibrutinib Plasma Exposure: Joint Analyses with Metabolite Data. <i>Pharmaceutics</i> , 2021, 14, 162. | 1.7 | 5 |
| 45 | Severe toxicity to capecitabine due to a new variant at a donor splicing site in the dihydropyrimidine dehydrogenase (DPYD) gene. <i>Cancer Management and Research</i> , 2018, Volume 10, 4517-4522. | 0.9 | 4 |
| 46 | Estimation of Unbound Carboplatin Clearance From Total Plasma Concentrations as a Means of Facilitating Therapeutic Drug Monitoring. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 66-74. | 1.0 | 4 |
| 47 | Population pharmacokinetic and pharmacodynamic modeling of capecitabine and its metabolites in breast cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 229-239. | 1.1 | 4 |
| 48 | Exhaustive single nucleotide polymorphism (SNP) analysis of DPYD exome in breast cancer patients (pts) receiving capecitabine.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2571-2571. | 0.8 | 4 |
| 49 | Diversity of dose-individualization and therapeutic drug monitoring practices of platinum compounds: a review. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 907-925. | 1.5 | 3 |
| 50 | Pharmacogenetic Study of Trabectedin-Induced Severe Hepatotoxicity in Patients with Advanced Soft Tissue Sarcoma. <i>Cancers</i> , 2020, 12, 3647. | 1.7 | 3 |
| 51 | Multicentric phase II trial of TI-CE high-dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors. <i>Cancer Medicine</i> , 2021, 10, 2250-2258. | 1.3 | 3 |
| 52 | Pharmacokinetic and Pharmacogenetic Study of Etoposide in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors. <i>Pharmaceutical Research</i> , 2020, 37, 147. | 1.7 | 2 |
| 53 | Severe toxicity of capecitabine in a patient with DPD deficiency after a safe FEC-100 experience: why we should test DPD deficiency in all patients before high-dose fluoropyrimidines. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 579-583. | 1.1 | 2 |
| 54 | DPYD Exome, mRNA Expression and Uracil Levels in Early Severe Toxicity to Fluoropyrimidines: An Extreme Phenotype Approach. <i>Journal of Personalized Medicine</i> , 2021, 11, 792. | 1.1 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Individualization of high dose carboplatin based on therapeutic drug monitoring (TDM) for the treatment of testicular germ cell tumors (TICE protocol): Results of a multicenter phase II study.. Journal of Clinical Oncology, 2017, 35, 4554-4554. | 0.8 | 1 |
| 56 | Laparoscopically Assisted Heated Intra-Operative Intraperitoneal Chemotherapy (HIPEC): Technical Aspect and Pharmacokinetics Data. , 2009, , 343-351. | | 1 |
| 57 | Pharmacogenomics in solid cancers and hematologic malignancies: improving personalized drug prescription. Therapie, 2021, , . | 0.6 | 1 |
| 58 | Investigation of predictive factors of response in patients with squamous-cell carcinoma of the head and neck (SCCHN) given neo-adjuvant erlotinib before surgery, updated results of a single institution experience. Radiotherapy and Oncology, 2007, 82, S31-S32. | 0.3 | 0 |
| 59 | 123 INVITED Application of Population PK-PD Methods in Oncology. European Journal of Cancer, 2011, 47, S30. | 1.3 | 0 |
| 60 | Reply to the letter addressed by Amr A. EL-Arabey "Dual function of OCT-2 and MATE1 in Cisplatin induced nephrotoxicity". Pharmacological Research, 2017, 119, 494. | 3.1 | 0 |